DBV Technologies to Participate in Upcoming ACAAI 2024 Congress
October 18 2024 - 3:30PM
UK Regulatory
DBV Technologies to Participate in Upcoming ACAAI 2024 Congress
Châtillon, France, October 18, 2024
DBV Technologies to Participate in Upcoming
ACAAI 2024 Congress
DBV Technologies (Euronext: DBV – ISIN:
FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage
biopharmaceutical company, today announced upcoming participation
at the American College of Allergy, Asthma & Immunology (ACAAI)
Annual Scientific Meeting, October 24 – 28th, 2024 in
Boston, Massachusetts.
This year’s meeting will feature a “Product
Theater” on What Defines an Optimal Peanut Allergy
Treatment? During this panel discussion, Drs. Shahzad Mustafa,
Edwin Kim, Julia Upton, and CEO of Food Allergy Research and
Education (FAACT), Eleanor Garrow-Holding will engage in a
discussion around hallmarks of an optimal treatment for peanut
allergy, focusing on the goals of efficacy, safety, and
practicality. The Product Theater is scheduled for Saturday,
October 26th, from 11:35 a.m. to 1:00 p.m. EDT.
DBV is also sponsoring the
33rd Annual FIT Bowl, a game show-type
competition that tests allergy, asthma, and immunology knowledge of
participating teams from training programs around the country. The
competition is set to be held on Saturday, October 26th,
from 5:45 p.m. to 7:45 p.m. EDT. In addition, DBV is a 2024 ACAAI
Benefactor Level Corporate Council Member. The Company will also
host a booth in the ACAAI Exhibit Hall from Friday, October
25th – Monday, October 28th.
“We are very pleased to join our peers in
food allergy at ACAAI again this year, particularly after recently
completing enrollment for VITESSE in children 4 – 7 years
old,” said Dr. Pharis Mohideen, Chief Medical Officer
of DBV Technologies. “Our global collaboration enabled
us to reach this critical milestone. DBV continues to advance our
regulatory progress with the Viaskin®
peanut patch in 1 – 3-year-olds and 4 – 7-year-olds. We look
forward to opportunities at the ACAAI to further discuss the unmet
medical need in peanut allergy and explore ways we can work
together across the community to support developments in food
allergy.”
DBV Presentation:
Product Theater (non-CME)
“What Defines an Optimal Peanut Allergy
Treatment?” featuring participation from Dr. Shahzad
Mustafa, Rochester Regional Health, Dr. Edwin Kim, UNC Pediatric
Allergy & Immunology, Dr. Julia Upton, MPH, The Hospital for
Sick Children and Eleanor Garrow-Holding, CEO of Food Allergy and
Anaphylaxis Connection Team (FAACT).
- Presentation Date: Saturday,
October 26th
- Presentation Time: 11:35 a.m. to
1:00 p.m. EDT
- Session/location: HCC, Level 2,
Exhibit Halls C & D, Product Theater #2
The Viaskin® Peanut patch is the Company’s lead
product candidate designed to reduce the risk of allergic reactions
due to accidental exposure to peanuts. An investigational,
non-invasive, once-daily epicutaneous patch, the Viaskin Peanut
patch seeks to deliver microgram quantities of peanut antigen to
re-educate the immune system. The safety and efficacy of the
Viaskin Peanut patch have not yet been established by the U.S. Food
and Drug Administration or the European Medicines Agency.
About DBV Technologies
DBV Technologies is a clinical-stage biopharmaceutical company
developing treatment options for food allergies and other
immunologic conditions with significant unmet medical need. DBV is
currently focused on investigating the use of its proprietary
Viaskin® patch technology to address food allergies, which are
caused by a hypersensitive immune reaction and characterized by a
range of symptoms varying in severity from mild to life-threatening
anaphylaxis. Millions of people live with food allergies, including
young children. Through epicutaneous immunotherapy (EPIT™), the
Viaskin® patch is designed to introduce microgram amounts of a
biologically active compound to the immune system through intact
skin. EPIT is a new class of non-invasive treatment that seeks to
modify an individual’s underlying allergy by re-educating the
immune system to become desensitized to allergen by leveraging the
skin’s immune tolerizing properties. DBV is committed to
transforming the care of food allergic people. The Company’s food
allergy programs include ongoing clinical trials of Viaskin Peanut
in peanut allergic toddlers (1 through 3 years of age) and children
(4 through 7 years of age).
DBV Technologies is headquartered in Châtillon,
France, with North American operations in Warren, NJ. The Company’s
ordinary shares are traded on segment B of Euronext Paris (Ticker:
DBV, ISIN code: FR0010417345) and the Company’s ADSs (each
representing one ordinary share) are traded on the Nasdaq Capital
Select Market (Ticker: DBVT).
For more information, please visit
www.dbv-technologies.com and engage with us on X (formerly Twitter)
and LinkedIn.
Forward Looking Statements
This press release may contain forward-looking statements and
estimates, including statements regarding DBV’s financial
condition, forecast of its cash runway, the therapeutic potential
of Viaskin® Peanut patch and EPIT™, designs of DBV’s anticipated
clinical trials, DBV’s planned regulatory and clinical efforts
including timing and results of communications with regulatory
agencies, the ability of any of DBV’s product candidates, if
approved, to improve the lives of patients with food allergies.
These forward-looking statements and estimates are not promises or
guarantees and involve substantial risks and uncertainties. At this
stage, DBV’s product candidates have not been authorized for sale
in any country. Among the factors that could cause actual results
to differ materially from those described or projected herein
include uncertainties associated generally with research and
development, clinical trials and related regulatory reviews and
approvals, and DBV’s ability to successfully execute on its budget
discipline measures. A further list and description of risks and
uncertainties that could cause actual results to differ materially
from those set forth in the forward-looking statements in this
press release can be found in DBV’s regulatory filings with the
French Autorité des Marchés Financiers (“AMF”), DBV’s filings and
reports with the U.S. Securities and Exchange Commission (“SEC”),
including in DBV’s Annual Report on Form 10-K for the year ended
December 31, 2023, filed with the SEC on March 7, 2024, and future
filings and reports made with the AMF and SEC by DBV. Existing and
prospective investors are cautioned not to place undue reliance on
these forward-looking statements and estimates, which speak only as
of the date hereof. Other than as required by applicable law, DBV
Technologies undertakes no obligation to update or revise the
information contained in this Press Release.
Viaskin is a registered trademark and EPIT is a
trademark of DBV Technologies.
Investor Contact
Katie Matthews
+ 1 (857) 529-2363
katie.matthews@dbv-technologies.com
Media Contact
Angela Marcucci
+1 646-842-2393
angela.marcucci@dbv-technologies.com
DBV Technologies (TG:DBV)
Historical Stock Chart
From Oct 2024 to Nov 2024
DBV Technologies (TG:DBV)
Historical Stock Chart
From Nov 2023 to Nov 2024